Free access
Research Article
1 November 2004

Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques


Chromosomal resistance to mupirocin in clinical isolates of Staphylococcus aureus arises from V588F or V631F mutations in isoleucyl-tRNA synthetase (IRS). Whether these are the only IRS mutations that confer mupirocin resistance or simply those that survive in the clinic is unknown. Mupirocin-resistant mutants of S. aureus 8325-4 were therefore generated to examine their ileS genotypes and the in vitro and in vivo fitness costs associated with them before and after compensatory evolution. Most spontaneous first-step mupirocin-resistant mutants carried V588F or V631F mutations in IRS, but a new mutation (G593V) was also identified. Second-step mutants carried combinations of previously identified IRS mutations (e.g., V588F/V631F and G593V/V631F), but additional combinations also occurred involving novel mutations (R816C, H67Q, and F563L). First-step mupirocin-resistant mutants were not associated with substantial fitness costs, a finding that is consistent with the occurrence of V588F or V631F mutations in the IRS of clinical strains. Second-step mutants were unfit, but fitness could be restored by subculture in the absence of mupirocin. In most cases, this was the result of compensatory mutations that also suppressed mupirocin resistance (e.g., A196V, E190K, and E195K), despite retention of the original mutations conferring resistance. Structural explanations for mupirocin resistance and loss of fitness were obtained by molecular modeling of mutated IRS enzymes, which provided data on mupirocin binding and interaction with the isoleucyl-AMP reactive intermediate.
The antibiotic mupirocin (see Fig. 6, structure 1) inhibits bacterial isoleucyl-tRNA synthetase (IRS) (24). It has potent activity against staphylococci and is used as a topical agent for the treatment of skin and postoperative wound infections and for prevention of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) (4).
The clinical use of mupirocin has resulted in the emergence of resistance in methicillin-susceptible S. aureus (MSSA), MRSA, and glycopeptide intermediate S. aureus (GISA) (5, 6, 9, 16, 29). Two mupirocin resistance phenotypes are exhibited (10). High-level resistance (MIC ≥ 512 μg/ml) results from acquisition of the mupA determinant that encodes a mupirocin-resistant IRS, whereas low-level resistance (MIC = 8 to 256 μg/ml) results from alteration of the native IRS as a consequence of spontaneous mutations in the ileS gene (2, 4, 8). Until recently, chromosomal mupirocin resistance arising through point mutations in ileS was considered clinically unimportant (4, 13). However, low-level mupirocin resistance appears to be more prevalent in clinical isolates than high-level resistance (6, 9, 25), and the emergence of low-level mupirocin resistance is thought to increase failure rates for nasal decolonization of MRSA (5, 12, 30).
IRS is a class I tRNA synthetase, a group characterized by an ATP-binding Rossman fold possessing consensus HXGX and GXKMSKS motifs (Fig. 1) (7). In clinical S. aureus isolates expressing low-level mupirocin resistance, amino acid substitutions have only been detected at two sites (V588F and V631F) in IRS that are located in the ATP-binding domain of the Rossman fold, a region which also overlaps the mupirocin binding site (2, 8, 26, 32). However, S. aureus exhibiting incremental increases in resistance to mupirocin can be selected in the laboratory after repeated exposure to increasing concentrations of the antibiotic (28). Such mutants, which probably arise from multiple genetic changes in ileS, have not yet appeared in clinical isolates of S. aureus (2, 8). Mutations in drug targets that confer resistance to other antibiotic classes can impose fitness costs on the organism (1). The occurrence of the V588F and V631F mutations in clinical isolates of mupirocin-resistant staphylococci appears to reflect the low-cost of these mutations in terms of bacterial fitness (15). In contrast, other ileS mutations may impose fitness costs, precluding their appearance in the clinic.
We provide here an extensive analysis of the in vitro and in vivo fitness costs for mupirocin resistance genotypes that have been identified in the clinic, as well as other novel mutations in the IRS of S. aureus. We also demonstrate that reversion, pseudoreversion, and compensatory evolution are all strategies capable of alleviating fitness costs associated with development of mupirocin resistance. Furthermore, we provide structural explanations for mupirocin resistance and accompanying reductions in fitness by molecular modeling of mutant IRS enzymes.


Bacteria and growth conditions.

The mutants described in the present study are derivatives of S. aureus 8325-4 (22). Strains were cultured aerobically at 37°C by using Iso-Sensitest broth (ISB) or Iso-Sensitest agar (ISA) (Oxoid, Basingstoke, United Kingdom).

Determination of susceptibility to mupirocin.

The lithium salt of mupirocin was a gift from Glaxo SmithKline Pharmaceuticals (Harlow, United Kingdom). MICs were determined by agar dilution on ISA with an inoculum in ISB of 106 CFU/spot (31). The MIC was defined as the lowest concentration of mupirocin that inhibited visible growth after 18 h of incubation at 37°C.

Determination of the mutation frequencies to resistance and MPC.

Mutation frequencies were determined by previously described methods (23). The mutant prevention concentration (MPC) is defined as the lowest concentration of an antibiotic that prevents bacterial colony formation from a culture containing 1010 CFU (33). Accordingly, late-logarithmic-phase cultures of the S. aureus 8325-4 growing in ISB were harvested by centrifugation and resuspended in fresh ISB at a final concentration of 1011 CFU/ml. Aliquots (200 μl) were incorporated into ISA plates containing serial twofold mupirocin dilutions in the range 0.06 to 1.0 μg/ml. The MPC was determined after incubation at 37°C for 48 h.

Determination of bacterial fitness.

Maximum doubling time and relative competitive fitness determinations were performed exactly as described previously (15).

PCR amplification and DNA sequencing of the ileS gene.

PCR amplification and sequencing of ileS genes from genomic DNA was performed as described previously (15).

Survival of S. aureus in vivo.

As a measure of in vivo fitness, the survival of S. aureus strains was determined in a murine wound abscess infection model (14). Mice were subcutaneously injected with 108 bacteria suspended in phosphate-buffered saline. After 7 days, the mice were killed, and the abscesses were recovered and homogenized in ISB. Bacteria in the homogenized lesions were quantified by plating on ISA, and the survival of mupirocin-resistant mutants was compared statistically with strain 8325-4 by using one-way analysis of variance and evaluation of minimum significance difference (P < 0.05) between means by the T method (27). The stability of mupirocin resistance genotypes during infection was confirmed by comparing the growth rates and susceptibility to mupirocin of in vivo isolates with their starting strains.

Selection of fitness-restored mutants.

Fitness-restored mutants were selected from unfit parent strains after serial transfer in nonselective ISB over a period of 7 to 9 days. Cultures of mupirocin-resistant mutants were grown in ISB at 37°C for 24 h, followed by transfer of aliquots to fresh ISB to initiate cultures containing ca. 106 CFU/ml. Serial transfer was continued until an increase in growth rate was detected, which is indicative of increased fitness in the population. Cultures were then plated onto nonselective ISA, and large, fast-growing colonies were selected for further study.

Molecular modeling.

Molecular models of the mutated enzymes were constructed by using the Swiss-PDB viewer v3.7 software (11) in conjunction with the structure files 1FFY.pdb (26) and 1JZQ.pdb (21). The lowest-energy conformations of the resulting mutated enzymes were then subjected to full energy minimization by using the MM2 force field within MacroModel (18) on Silicon Graphics O2 or Indy workstations. In order to simplify the computations, all calculations were performed on a 25-Å spherical portion of the protein centered on the ligand. For the energy minimizations, a 12-Å spherical region within this substructure centered on the ligand was defined in which all atoms, including those from the ligand, were allowed to freely move and atoms outside this region were frozen.


First-step mupirocin-resistant mutants.

Selection of antibiotic-resistant mutants through chromosomal mutations occurs in a mutant selection window in which the drug concentration lies between the MIC and the MPC (33). A mutant selection index of 31 (i.e., MPC divided by MIC) was obtained for S. aureus 8325-4 on the basis of an MPC of 0.5 μg/ml and MIC of 0.016 μg/ml. This indicates an intermediate vulnerability to the development of mupirocin resistance in S. aureus, which is less than that exhibited by rifampin but greater than that displayed by the majority of fluoroquinolones (33). We isolated and characterized mutants of strain 8325-4 that arose spontaneously after selection with 0.064 μg of mupirocin/ml (four times the MIC). The mutants displayed low-level resistance to mupirocin with MICs in the range 1 to 16 μg/ml (Table 1). The mutants arose with an overall frequency of (7.2 ± 0.9) × 10−8, which is consistent with single mutational events. Several mutants selected for sequencing of ileS revealed the V588F and V631F IRS amino acid substitutions also found in clinical isolates (Table 1). However, a third mutant class was identified involving a G593V mutation (Table 1). This genotype has not previously been identified in mupirocin-resistant S. aureus, but mutation at the equivalent locus in Methanobacterium thermoautotrophicum Marburg (G589D) confers mupirocin resistance (17) (Fig. 1).

Second-step mutations in ileS conferring elevated mupirocin resistance.

Mutants of S. aureus exhibiting elevated levels of resistance to mupirocin (MIC ≥ 16 μg/ml) have been isolated in vitro after stepwise exposure to increasing concentrations of the antibiotic (28). Although these resistant derivatives probably arise by accumulation of separate mutations within ileS, there are no DNA sequence data to support this hypothesis. Strains JGH-1, JGH-4, JGH-5, JGH-6, and JGH-8, which contain single mutations in ileS (Table 1), were therefore used as starting strains for the selection of higher-level resistant second-step mutants.
Second-step mutants were selected by plating onto ISA containing mupirocin at four times the respective MICs for the starting strain. This resulted in the recovery of mutants for which mupirocin MICs were in the range 16 to 128 μg/ml (Table 1). Short regions of the ileS were resequenced and resistance mutations detected. However, where no mutations were identified (JGH-13, JGH-15), the entire ileS gene was sequenced to reveal second-step mutations. In many cases the second mutation occurred at one of the sites (V588F or V631F) already identified in low-level mutants, resulting in the generation of double V588F/V631F or G593V/V631F mutants (Table 1). Antonio et al. (2) have suggested that V631F and V588F mutations may be mutually exclusive since considerable distortion of the hydrophobic domain of IRS would occur. Nevertheless, we show here that these mutations can coexist in IRS. Similarly, G593V and V631F mutations can be simultaneously tolerated in IRS. Three second-step mutations occurred at loci not previously implicated in mupirocin resistance (Table 1) involving the following changes: R816C (strain JGH-13), F563L (strain JGH-14) and H67Q (strain JGH-15).
Second step mutants arose with an overall frequency in the range of 4 × 10−10 to 8 × 10−10, which is less than the frequency for selection of first-step mutants. The reason that second-step mutations occur less frequently is unclear. However, this does not appear to be related to mutational target size since the numbers of sites at which new mutations arose during first- and second-step selections were similar (Fig. 1).

In vitro fitness of first-step mupirocin-resistant mutants.

Resistance to antibiotics arising from mutations in target genes can result in fitness costs that affect bacterial growth and survival (1, 20). Fitness costs associated with development of mutational resistance to mupirocin could be a factor that influences the prevalence of certain staphylococcal resistance genotypes in the clinic. In preliminary studies, we recently reported that the V588F mutation in clinical isolates of GISA is associated with low fitness costs (15). The fitness of other genotypes has not been examined, but it is possible that fitness costs may account for the low frequency of detection of the V631F resistance allele and, similarly, the apparent absence of G593V in clinical specimens. We have now expanded our preliminary analysis by determining the in vitro fitness of a number of strains derived from 8325-4 that contain V588F, V631F, or G593V mutations in IRS. Fitness was assessed by determining the doubling times of mutants and also by comparing their performance with the parental strain 8325-4 in mixed culture competition assays (Table 1 and Fig. 2).
The doubling times of six mutants containing the V588F alteration, two mutants containing the V631F alteration and two mutants containing the G593V alteration were not considerably different from the parental starting strain 8325-4 (Table 1). In mixed culture competition assays five of six strains containing the V588F mutation displayed a small loss of fitness, but the relative competitive fitness (W) never fell to <0.9. The G593V mutation was also associated with a small loss (6 to 8%) of fitness detectable by the mixed culture competition assay.
Strains carrying the V631F mutation (JGH-3 and JGH-4) were as fit as the parental strain (Table 1). However, although there were no significant differences in doubling times, there was an apparent reduction in W of ∼0.2 for three other strains containing V631F mutations (data not shown). In other systems, it is well known that compensatory mutations can arise in unfit antibiotic-resistant mutants that restore fitness and yet retain resistance (1, 20). Therefore, the V631F mutation might be initially associated with a small fitness cost that is ameliorated during subculture through intragenic or extragenic suppression. Nevertheless, no evidence for intragenic compensatory adaptation was found in fit strains possessing the V631F mutation.
The relatively modest fitness costs associated with the V588F and V631F mutations are in agreement with our earlier studies on GISA and consistent with the occurrence of these resistance genotypes in clinical isolates (2, 8, 15). Since the G593V resistance mutation does not appear to incur significant fitness costs, at least in vitro, it might arise in clinical isolates. Currently, this mutation has not been identified in clinical strains (2, 8, 15). However, more extensive surveys may reveal this genotype in the future.

In vitro fitness of second-step mupirocin-resistant mutants.

In addition to the very low mutation frequencies for the generation of double ileS mutants, another reason for the absence of such bacteria in clinical isolates might be poor fitness of strains with two mutations in IRS. Indeed, second-step mupirocin-resistant mutants displayed reduced fitness both in vitro and in vivo (Table 1 and Fig. 3).
The doubling time of mutants containing two ileS mutations was longer than that for first-step mutants or for the original mupirocin-sensitive parental strain 8325-4. For example, JGH-15 (carrying mutations V588F and H67Q) grew approximately three times more slowly than first-step mupirocin-resistant mutants or 8325-4. The second-step mutants also displayed loss of fitness in the mixed-culture competitive fitness assay with W values from 0.24 to 0.63 (Table 1).

Correlation between fitness costs measured by maximum doubling times and mixed-culture competition.

As previously mentioned, the exponential growth of resistant bacteria was affected by mupirocin resistance, and this was most pronounced in second-step mutants. Furthermore, a positive (R2 = 0.89), correlation was observed between the doubling times and W of mupirocin-resistant staphylococci (Fig. 2). Consequently, at least in the case of mupirocin resistance in S. aureus, growth rate determinations provide a simple representative measure of fitness trends without the need for laborious mixed-culture competition assays.

In vivo fitness of first- and second-step mupirocin-resistant mutants.

Significant costs of resistance observed in vitro usually indicate situations where resistance would impose a fitness burden on the organism in natural populations (1). Nevertheless, the survival of S. aureus 8325-4 and selected first- and second-step mupirocin-resistant mutants, which carry mupirocin resistance genotypes previously identified in clinical strains, was also examined in a murine wound abscess infection model (Fig. 3). The number of viable organisms in the infectious dose was established at the start of the experiment, and the number of survivors after 7 days of infection was determined by plating samples of homogenized skin lesions onto ISA. The surviving fraction of strain JGH-12 (double IRS mutant, V631F/V588F) was significantly lower than the wild-type 8325-4 (Fig. 3). In contrast, survival of the first-step mupirocin-resistant mutants JGH-4 (V631F) and JGH-6 (V588F) was not significantly different from 8325-4. The mupirocin MICs and doubling times of independent colonies recovered from the mice were similar to the values for the strains used to initiate the infections (data not shown). This implies genetic stability of mupirocin resistance within ileS during the murine infections.
Although the experiments reported here did not reveal a statistically significant difference in the in vivo fitness of strains 8325-4 and JGH-6, there is, nevertheless, an indication that the V588F mutation in strain JGH-6 might be associated with increased fitness compared to the parental starting strain 8325-4 (Fig. 3). However, further experiments involving infection of five mice with mixed cultures of strains 8325-4 and JGH-6 provided no evidence that JGH-6 was fitter than 8325-4 (data not shown).
Overall, the murine data provide a correlation between in vitro and in vivo fitness and further indicate that the clinically occurring V588F and V631F mutations are not associated with significant fitness costs, whereas second-step mutants, such as JGH-12 (V631F/V588F), which have not been reported clinically, possess significant fitness burdens.

Stability of second-step mupirocin-resistant mutants.

In the absence of continued antibiotic selection pressure, the fitness of unfit antibiotic-resistant mutants can be restored by several mechanisms, one of which involves reversion of resistant alleles by back mutation (1). Consequently, if mupirocin-resistant mutants with more than one mutation in ileS can arise in the clinic, the failure to detect them in clinical isolates could reflect reversion to produce fitter strains containing only one resistance allele. We therefore examined whether resistance was lost and fitness restored when unfit second-step mupirocin-resistant mutants (JGH-11 to JGH-15) were serially subcultured in the absence of mupirocin for up to 9 days by daily transfer into fresh medium.
At the end of each subculture, samples were taken for determination of mupirocin MICs. Serial subculture of mupirocin-resistant strains JGH-11, JGH-13, JGH-14, and JGH-15 led to progressive reduction of organisms expressing higher levels of resistance to mupirocin within the cultures and replacement by derivatives for which mupirocin MICs were lower (Fig. 4). For instance, the MIC of mupirocin against JGH-15 was initially 128 μg/ml. However, after serial subculture in the absence of mupirocin for 4 days, the culture contained daughter cells with only low-level resistance (mupirocin MIC = 8 μg/ml), which remained stable for the remainder of the serial subculture. With the exception of JGH-12 (see below), similar results were obtained with the other higher level mupirocin-resistant mutants, which all gave rise to stable, lower-level mupirocin-resistant populations within 4 to 7 days of serial subculture (Fig. 4).
In contrast to the other higher level mupirocin-resistant strains, resistance was stable in strain JGH-12 during the course of 9 days serial subculture since starting and final MICs were 32 μg/ml. However, organisms recovered at the end of this experiment were fitness compensated (see below).

Fitness of strains recovered from serial subculture and further genetic analysis.

During serial subculture the emergence of lower-level mupirocin-resistant subpopulations in cultures of JGH-11, JGH-13, JGH-14, and JGH-15 coincided with progressive increases in growth rates of the mixed populations (Fig. 4). This is consistent with reversion of one of the mutated alleles in the ileS gene of the parent strains to produce derivatives with restored fitness and reduced resistance or accumulation of further mutations that act to suppress both the resistance phenotype and fitness cost of the existing allele (pseudoreversion). Elevated growth rates were also recorded in cultures of JGH-12 after 3 days of subculture even though resistance of JGH-12 to mupirocin was unaltered through 9 days of serial subculture. This probably reflects the appearance of an intragenic or extragenic compensatory mutation that restores fitness but allows resistance to be retained (1).
The more rapidly growing colonies obtained from the mupirocin-resistant strains were therefore presumptive fitness-restored mutants. A number of these colonies were retained for further analysis. They were designated strains JGH-16 to JGH-27 (Table 1). Strains JGH-16 to JGH-27 exhibited doubling times (range, 38 to 52 min) and W values (range, 0.79 to 1) that indeed indicated partial or complete restoration of fitness compared to their original unfit parental starting strains (Table 1).
To determine whether compensatory or back mutations were responsible for fitness restoration, the entire ileS gene of the fitness-restored mutants was sequenced and mutations were identified. Back mutation of the second-step mutation (Q67H) in strain JGH-15 to create JGH-25 restored fitness by reinstating the HMGH sequence (Fig. 1 and Table 1). However, back mutation of resistance alleles was not detected in other fitness-restored strains. Intragenic and extragenic compensatory mutations that suppressed the effects of the resistance genotypes were inferred from sequencing data. For example, in strains JGH-22 and JGH-23 (both derived from JGH-13) either E195K (JGH-22) or A196V (JGH-23) mutations were found, in addition to the previously identified resistance mutations V588F and R816C. One strain, JGH-21 (derived from strain JGH-13) seemed to have acquired an extragenic mutation in addition to the compensatory mutation E195K. Acquisition of this uncharacterized extragenic mutation may explain why strain JGH-21 showed greater susceptibility to mupirocin (MIC = 0.5 μg/ml) compared to JGH-22 (MIC = 4 μg/ml). Compensatory mutations (E190K or A196V) were detected in strains JGH-16 to JGH-19 (each derived from JGH-11) in regions adjacent to compensatory mutations found in JGH-22 and JGH-23 (each derived from JGH-13). Intragenic mutations were not found in JGH-20 (derived from JGH-12) or JGH-24 (derived from JGH-14), a finding consistent with a role for extragenic compensatory mutations in restoring the fitness of these strains.
Restoration of fitness by intragenic suppression usually involves compensation by second site mutations that restore fitness and retain resistance (1, 20). Therefore, the situation described here is somewhat unusual since intragenic (and indeed some extragenic) mutations produced derivatives that exhibited lower-level resistance to mupirocin, despite retention of both original mutations that conferred high-level resistance. Fitness costs may be alleviated in these pseudorevertants by introduction of compensatory mutations that alter IRS conformation, restoring catalytic activity and susceptibility to mupirocin, despite the presence of mutations previously conferring high-level mupirocin resistance whose expression is now partially suppressed.

Molecular modeling of the mupirocin binding site in the IRS of resistant mutants.

In order to probe the molecular effects of mutations upon mupirocin binding, we constructed molecular models of both the first- and second-step IRS mutants and used these to both quantify the effect of the mutations upon the binding energy for mupirocin and to try to establish the precise interactions responsible for any changes in binding energy. The calculated binding energies of mupirocin within these complexes are summarized below (Table 2). In general, there appears to be a broad correlation between the calculated mupirocin-IRS binding energy and the measured mupirocin MIC.
As can be seen, all of the mutant enzymes contained lower mupirocin-protein binding energies than that calculated for the wild type (Table 2). In addition, the most dramatic decreases were found within the second-site mutants, in keeping with elevated levels of mupirocin resistance. Detailed examination of the molecular models appeared to reveal some of the structural factors affecting the mupirocin binding of these mutants.


Glycine 593 is located in the loop that makes direct contact with the tRNA via a hydrogen bond between the backbone carbonyl and the 2′-OH of G-68 (Fig. 5). Substitution for valine locates the new hydrophobic side chain close to this hydroxyl and appears to result in a net repulsion. This induces a slight movement of the loop toward the side chain of the neighboring methionine 589, which in turn appears to move the backbone carbonyl unit of valine 588 nearer to the hydrophobic region of mupirocin bordering C-8′ and C-9′. The resulting repulsion also appears to lengthen the H-bond between the valine 588 NH and the O = C1 carbonyl of mupirocin by 0.2 Å (Fig. 5). This apparent relaying of the steric interaction experienced within the newly mutated residue also appears to move some of the carbon atoms within the fatty acid side chain of mupirocin. Since this resides in a fairly narrow hydrophobic channel, this movement may also contribute to weaker binding of antibiotic to the enzyme.


In the wild-type enzyme, valine 588 lines the hydrophobic pocket that interacts with the fatty acid side chain of mupirocin. Upon mutation to phenylalanine, the increased bulk of the benzyl side chain results in steric repulsion at C-1 and C-2 of mupirocin and lengthens the valine 588 NH/O = C1 H bond by 0.67 Å (Fig. 5).


As in the case of G593V, V631F appears to affect mupirocin binding via a “steric relay” mechanism. Valine 631 is stacked above valine 588 and, upon mutation to phenylalanine, the increased bulk of the benzyl side chain repels that of valine 588. The resulting torsional movement pushes the carbonyl oxygen of valine 588 closer to mupirocin and again, distorts the fatty acid side chain of the antibiotic, and weakens the valine 588 derived H bond, which becomes lengthened by 0.22 Å (Fig. 5).


Increasing the size of the side chain at position 631 from isopropyl to benzyl in combination with the effect of the G593F mutation, as described previously, increases further the steric repulsion between the side chains at positions 631 and 588 and, again, leads to further stretching of the V588-mupirocin H bond by 0.13 Å and, perhaps more importantly, further increases the distortion along the fatty acid side chain of the antibiotic (Fig. 5).


Since these two amino acids are essentially stacked one above the other, the steric repulsion between the two benzyl side chains in this mutant appears to be considerable such that the movement of F588 away from F631 appears to abolish the F588-mupirocin H bond with considerable distortion of the mupirocin fatty acid moiety by up to 1.18 Å from its position in the wild-type enzyme.


In addition to the effect of the V588F mutation via its direct interaction with mupirocin as noted above, the F563L mutation appears to be a further example of a “relayed” steric clash with mupirocin. The calculated structure indicates that the leucyl side chain at position 563, which is located within a looped region, will undergo steric repulsion with L582, which is directly opposite on the adjacent peptide chain. This appears to result in torsional strain within the loop and in particular moves the side chain of tryptophan 562 close to the C-14 methyl group of mupirocin.


As for the previously described double mutant, in addition to the direct effect of the V588F mutation on mupirocin binding, the H67Q mutation also appears to directly affect the interaction with mupirocin and locates the carbonyl group from the amide side chain of glutamine in close proximity to the hydrophobic portion of the sugar-like ring of mupirocin, centered around C-16 and C-8.

Comparison of computational predictions for mupirocin binding with in vitro IRS binding data.

It has been reported (3) that an ethyl ester variant of mupirocin (therefore containing a much-shortened alkyl chain) shows a 10-fold reduction in activity against S. aureus IRS compared to mupirocin (ki = 0.19 versus 0.017 nM, respectively). Using the equation ΔG = −RT × lnki (wherein ΔG is the change in free energy, R is the gas constant, T is the temperature, and ki is the dissociation constant of the enzyme-inhibitor complex), free-energy changes upon dissociation (ΔG) of 13.25 and 14.68 kcal/mol, respectively, are obtained. Clearly, the magnitudes of these measured free energies reflect the total change in the energetics of the system during binding (including changes in solvation, entropy, bond enthalpies, etc.). Therefore, they cannot be directly compared to the calculated gas-phase enthalpies of binding shown in Table 2, which simply reflect the relative changes in bond enthalpy between substrate and enzyme resulting from substrate binding. Nevertheless, the reduced affinity of the shortened alkyl chain variant for IRS compared to that of mupirocin is consistent with our present findings concerning the effect of mutations on the region of the protein bordering the binding pocket of the alkyl chain of mupirocin.

Molecular modeling of isoleucyl-AMP binding.

The variation in fitness costs associated with the various mutants could result from changes in the binding of the enzyme to the reactive isoleucyl-AMP intermediate generated during acylation of the tRNA. We have therefore probed the structural details within a series of models that examine the binding energies of the reactive isoleucyl-AMP intermediate (Fig. 6, structure 2) generated during acylation of the tRNA. The models of this reactive complex were constructed first by docking a model of structure 2 into the enzyme active site by using the automated molecular docking program AutoDock (19). The lowest-energy complex was then used to create the various mutant structures, which were then subjected to energy minimization as described above. To date, there is no available X-ray structural data for the S. aureus IRS containing the reactive intermediate, with which direct comparison of IRS/inhibitor models could be made.
However, the X-ray crystal structure of a sulfonamide-based inhibitor (Fig. 6, structure 3), designed to mimic a reactive intermediate (Fig. 6, structure 2) with an IRS, has been reported (21). Comparison of the models with this structure reveals remarkable similarity with essentially all of the observed inhibitor/enzyme contacts present within the active complex/enzyme models (Fig. 7). In particular, hydrogen bonds are predicted between the 2′-OH and backbone N of Q554; the 3′-OH and side chain of Q554; a phosphate oxygen and backbone NH of Y58, and between the leucyl NH3 and the carbonyl of P56. Similarly, the purine ring takes part in H bonding involving N5 and the backbone NH of V588, and between N7 and H585 (Fig. 7). In addition, the reactive intermediate and mupirocin bind in very similar regions within the enzyme (Fig. 8), with the epoxide ring of mupirocin occupying the same space as the phosphate unit in the intermediate. The central sugar core of both systems is also seen to overlap. The close similarity in binding regions for mupirocin and the reactive intermediate may further explain why major conformational changes that result in higher-level resistance also incur significant fitness reductions. However, an important difference occurs in the region of the extended hydrophobic side chain of mupirocin, which is essentially unoccupied in the reactive intermediate-containing models.
Table 2 lists the calculated binding energies of the model of the reactive intermediate within the mutant enzymes. Interestingly, the binding energies within all of the first-step mutants are essentially the same as that calculated for the wild-type system. In particular, as outlined above, the G593V mutation occurs in a region several angstroms away from the phosphorylated intermediate binding cavity. Similar observations apply for the V631F and V588F first-step mutations (Fig. 9). These mutations appear to have little effect upon the binding of the acylated intermediate due to the absence of any part of the ligand in these regions.
For the second-step mutants the calculated binding affinities show a marked decrease relative to the first-step mutants, with that from V588F/F563L exhibiting the lowest value (Table 2). Inspection of the models reveals the origins of the decreased binding energies. For the G593V/V631F mutant, the presence of the V631F mutation in particular appears to induce a small movement in the adjacent peptide strand at V588 which in turn induces a further movement (by ∼0.55 Å) in the neighboring peptide loop at position M65. This widens the hydrophobic pocket holding the purine ring of the substrate, and results in movement of the substrate to better fit the wider pocket. This in turn alters the hydrogen bond distances between the substrate and enzyme in the region of the isoleucine fragment, most noticeably involving Y58 NH and one of the phosphate oxygens, which is lengthened by ∼0.1 Å and also that between the NH3 of the substrate and the side chain of D95, which increases in length by 0.2 Å. This widening of the pocket binding the purine ring is also seen in the V631F/V588F mutant and analogous side chain interactions appear to induce the same type of distortion in substrate binding and H-bond lengths.
The V588F/F563L mutation also appears to disrupt the H bonding and perhaps also the hydrophobic interactions at the isoleucyl end of the substrate. This seems to result from loss of the edge-to-face interaction between the original aromatic ring present at F563 and the phenolic ring of Y559. This appears to widen the hydrophobic cavity carrying the isoleucyl chain of the substrate and also lengthens the H bonds within this region, particularly that between the NH3 of the substrate and the side chain of D95 (by 0.23 Å).
This same distortion of the isoleucyl binding pocket also appears to be responsible for the decreased affinity observed for the substrate in the V588F/H67Q mutant. In this case, however, it originates from loss of the original face-to-face interaction involving the imidazole rings of H67 and H64. In the mutant, the amide side chain at Q67 is forced to lie nearer the substrate resulting in a steric repulsion, which again lengthens the H bond at the NH3 and phosphate positions of the substrate by 0.1 and 0.2 Å, respectively.
The general trend within the binding energies broadly correlates with the fitness cost measurements and appears to show that the fitness within the various mutant IRS enzymes is a direct result of changes in the efficiency of binding of the key isoleucyl phosphate ester intermediate.


Mutations conferring antibiotic resistance with only low fitness costs may survive for very long periods in natural populations since there will be no counterselection favoring loss of resistance. The fitness studies reported here suggest that first-step V588F and V631F ileS mutations conferring low-level mupirocin resistance are low-cost mutations both in vitro and in vivo, a finding consistent with the occurrence of these mutations in clinical isolates (2, 8).
We observed in the laboratory that higher levels of mupirocin resistance could be generated by selection of second-step mutants from first-step hosts. Such second-step mutants exhibited fitness costs associated with the accumulation of a second mutation in ileS. Studies on fitness costs imposed by other antibiotic resistance mutations (1, 20) do not necessarily preclude the clinical appearance of mupirocin-resistant mutants with more than one ileS mutation because compensatory mutations to alleviate fitness might occur. Indeed, the studies presented here show that fitness burdens imposed by two mutations in ileS are more frequently relieved by independent compensatory mutations rather than back mutations in the specific allele conferring resistance, at least in vitro. Nevertheless, there is currently no evidence that mupirocin-resistant mutants with more than one mutation in ileS arise in the clinic (2, 8, 15). Furthermore, although several mutations of uncertain significance have been located in the ileS of clinical isolates (2, 8), none of them corresponds to the intragenic compensatory mutations we report here in laboratory strains. We therefore conclude that clinical selection of mupirocin-resistant strains possessing two mutations in ileS, if it occurs, must be a rare event. There are a number of possible explanations for this situation. In the first instance the probability of a strain simultaneously acquiring two mutations in ileS appears to be very low since combination of the individual mutation frequencies for generation of first- and second-step mutants provides a theoretical simultaneous two-step mutation frequency of ∼10−18. Nevertheless, stepwise selection of two mutations conferring resistance could occur as a result of poor compliance or suboptimal application of mupirocin. Consequently, lack of fitness is the most likely explanation for the absence of resistant double mutants in clinical isolates.
In addition to the clinical implications of the work reported here, we provide a structural understanding of the mutations conferring mupirocin resistance and their effects upon bacterial fitness. For example, there was a correlation between binding energies for mupirocin-IRS interactions and degree of resistance to the antibiotic. Furthermore, the lack of fitness in some mupirocin-resistant mutants could be explained by decreased binding of the reactive intermediate Ile-AMP in the IRS enzyme. Unfortunately, it was not possible to extend the structural studies to the third-site fitness-compensated mutants since these were generally located at positions outside the 12-Å sphere centered on mupirocin within which the energy calculations could be performed.
FIG. 1.
FIG. 1. Amino acid sequence alignment of three regions in the S. aureus (S.a) IRS enzyme involved in mupirocin resistance, with the IRS enzymes of Escherichia coli K-12 (E.c; GenBank accession no. SYECIT ), M. thermoautotrophicum Marburg (M.a; SYEXI), and Thermus thermophilus (T.t; P56690). The consensus sequences involved in ATP binding are boxed. Important amino acids involved in isoleucine binding are underlined. First- and second-step mutations (superscripts 1 and 2) in the S. aureus IRS are shown in boldface above the wild-type amino acid.
FIG. 2.
FIG. 2. Correlation between fitness of mupirocin-resistant mutants evaluated by doubling time and competitive fitness (W).
FIG. 3.
FIG. 3. Survival of mupirocin-resistant mutants in a murine wound abscess model.
FIG. 4.
FIG. 4. Changes occurring in mupirocin susceptibility (A) and doubling time (B) during passage of unfit second-step mupirocin-resistant mutants.
FIG. 5.
FIG. 5. Detail of mupirocin-binding region in S. aureus IRS. Residues that have been mutated are shown in green, and the mutation is indicated in italics. Nucleoside residue G68, in Ile tRNA, is also included.
FIG. 6.
FIG. 6. Structures of mupirocin (structure 1), the reactive intermediate (structure 2), and the sulfonamide-based mimic (structure 3).
FIG. 7.
FIG. 7. Overlay of the X-ray crystal structure of IRS from T. thermophilus (green) containing the reactive intermediate mimic (yellow) on the modeled reactive intermediate (Ile-AMP) bound within the IRS of S. aureus.
FIG. 8.
FIG. 8. Comparative views of bound structures of mupirocin (top), reactive intermediate (red, bottom), and superposition of structures (middle) in the IRS of S. aureus.
FIG. 9.
FIG. 9. Detail of the acylated intermediate binding region in IRS of S. aureus. Residues that have been mutated are shown in green, and the mutation is indicated in italics.
TABLE 1. First-step, second-step, and compensatory mutations associated with mupirocin resistance and their associated effects on resistance, bacterial growth, and fitness
StrainParentMupirocin MIC (μg/ml)Mean ± SD Substitutionsa 
   Doubling time (min)Competitive fitness (W)Nucleotide substitutions in ileSAmino acid substitutions in IRS
8325-4 0.01637.5 ± 0.51.00NANA
First-step mupirocin-resistant mutants      
    JGH-18325-4140.9 ± 1.60.92 ± 0.02G1778TG593V
    JGH-28325-4243.4 ± 0.80.94 ± 0.05G1778TG593V
    JGH-38325-4238.9 ± 0.30.99 ± 0.08G1891TV631F
    JGH-48325-4241.6 ± 0.71.00 ± 0.03G1891TV631F
    JGH-58325-4840.7 ± 0.70.94 ± 0.04G1762TV588F
    JGH-68325-4841.0 ± 1.00.95 ± 0.01G1762TV588F
    JGH-78325-4842.0 ± 0.70.93 ± 0.01G1762TV588F
    JGH-88325-4838.8 ± 1.80.96 ± 0.05G1762TV588F
    JGH-98325-41639.1 ± 2.00.99 ± 0.03G1762TV588F
    JGH-108325-41640.0 ± 0.50.94 ± 0.04G1762TV588F
Second-step mupirocin-resistant mutants      
    JGH-11JGH-11666.7 ± 4.60.63 ± 0.03G1778T, G1891TG593V, V631F
    JGH-12JGH-43258.8 ± 0.70.57 ± 0.03G1891T, G1762TV631F, V588F
    JGH-13JGH-564102.6 ± 5.20.32 ± 0.06G1762T, C2446TV588F, R816C
    JGH-14JGH-6128120.4 ± 4.00.24 ± 0.08G1762T, T1687CV588F, F563L
    JGH-15JGH-8128141.0 ± 29.00.33 ± 0.01G1762T, T201AV588F, H67Q
Fitness-restored mutants      
    JGH-16JGH-11240.4 ± 0.80.99 ± 0.02G1778T, G1891T, C587TG593V, V631F, A196V
    JGH-17JGH-11240.2 ± 1.00.94 ± 0.07G1778T, G1891T, C587TG593V, V631F, A196V
    JGH-18JGH-11238.3 ± 0.41.00 ± 0.00G1778T, G1891T, G568AG593V, V631F, E190K
    JGH-19JGH-11240.1 ± 1.51.00 ± 0.01G1778T, G1891T, G568AG593V, V631F, E190K
    JGH-20JGH-123239.2 ± 2.51.01 ± 0.05G1891T, G1762T, not detectedV631F, V588F, not detected
    JGH-21JGH-130.540.0 ± 0.40.83 ± 0.08G1762T, C2446T, G583AV588F, R816C, E195K
    JGH-22JGH-13438.6 ± 2.40.95 ± 0.01G1762T, C2446T, G583AV588F, R816C, E195K
    JGH-23JGH-13839.3 ± 0.40.93 ± 0.08G1762T, C2446T, C587TV588F, R816C, A196V
    JGH-24JGH-14837.8 ± 1.50.98 ± 0.01G1762T, T1687C, not detectedV588F, F563L, not detected
    JGH-25JGH-15839.3 ± 0.70.96 ± 0.05G1762T, T201A, A201TV588F, H67Q, Q67H
    JGH-26JGH-15849.6 ± 4.50.79 ± 0.07G1762T, T201A, C1188AV588F, H67Q, H396Q
    JGH-27JGH-151652.0 ± 5.00.79 ± 0.07G1762T, T201A, C1188AV588F, H67Q, H396Q
The mutations in ileS and IRS occurring at each step-wise selection are shown in boldface. NA, not applicable.
TABLE 2. Calculated mupirocin and Ile-AMP binding energies for IRS in relation to mupirocin susceptibility and fitness costs in S. aureus
Amino acid substitutions in IRSBinding energies of mupirocin (ΔEmup [kcal/mol])MIC (μg/ml)Binding energies of Ile-AMP (ΔEIle-AMP [kcal/mol])Fitness costa
First-step mupirocin-resistant mutants    
Second-step mupirocin-resistant mutants    
    G593V, V631F34.111635.62High
    V631F, V588F34.733236.29High
    V588F, F563L28.7512830.09High
    V588F, H67Q29.5212835.59High
Refer to Table 1 for fitness data.


J.G.H. acknowledges the receipt of a Ph.D. Scholarship from the Association of Commonwealth Universities (United Kingdom).


Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol.2:489-493.
Antonio, M., N. McFerran, and M. J. Pallen. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.46:438-442.
Brown, M. J. B., L. M. Mensah, M. L. Doyle, N. J. P. Broom, N. Osbourne, A. K. Forrest, C. M. Richardson, P. J. O'Hanlon, and A. J. Pope. 2000. Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry39:6003-6011.
Cookson, B. D. 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother.41:11-18.
Decousser, J. W., P. Pina, J. C. Ghnassia, J. P. Bedos, and P. Y. Allouch. 2003. First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin. Eur. J. Clin. Microbiol.22:318-319.
Deshpande, L. M., A. M. Fix, M. A. Pfaller, and R. N. Jones. 2002. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, E-test, and reference dilution methods. Diagn. Microb. Infect. Dis.42:283-290.
Eriani, G., M. Delarue, O. Poch, J. Gangloff, and D. Moras. 1990. Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs. Nature347:203-206.
Fujimura, S., Y. Tokue, and A. Watanabe. 2003. Isoleucyl-tRNA synthetase mutations in Staphylococcus aureus clinical isolates and in vitro selection of low-level mupirocin-resistant strains. Antimicrob. Agents Chemother.47:3373-3374.
Fujimura, S., and A. Watanabe. 2003. Survey of high- and low-level mupirocin-resistant strains of methicillin-resistant Staphylococcus aureus in 15 Japanese hospitals. Chemotherapy49:36-38.
Gilbart, J., C. R. Perry, and B. Slocombe. 1993. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-transfer RNA-synthetases. Antimicrob. Agents Chemother.37:32-38.
Guex, N., and M. C. Peitsch. 1997. Swiss-Model and the Swiss-Pdb viewer: an environment for comparative protein modeling. Electrophoresis18:2714-2723.
Harbarth, S., N. Liassine, S. Dharan, P. Herrault, R. Auckenthaler, and D. Pittet. 2000. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.31:1380-1385.
Henkel, T., and J. Finlay. 1999. Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J. Chemother.11:331-337.
Horsburgh, M. J., M. O. Clements, H. Crossley, E. Ingham, and S. J. Foster. 2001. PerR controls oxidative stress resistance and iron storage proteins and is required for virulence in Staphylococcus aureus. Infect. Immun.69:3744-3754.
Hurdle, J. G., A. J. O'Neill, and I. Chopra. 2004. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J. Antimicrob. Chemother.53:102-104.
Janssen, D. A., L. T. Zarins, D. R. Schaberg, S. F. Bradley, M. S. Terpenning, and C. A. Kauffman. 1993. Detection and characterization of mupirocin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.37:2003-2006.
Jenal, U., T. Rechsteiner, P. Y. Tan, E. Buhlmann, L. Meile, and T. Leisinger. 1991. Isoleucyl-tRNA synthetase of Methanobacterium thermoautotrophicum Marburg: cloning of the gene, nucleotide sequence, and localization of a base change conferring resistance to pseudomonic acid. J. Biol. Chem.266:10570-10577.
Mohamadi, F., N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, and W. C. Still. 1990. Macromodel: an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem.11:440-467.
Morris, G. M., D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, and A. J. Olson. 1998. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem.19:1639-1662.
Nagaev, I., J. Bjorkman, D. I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol.40:433-439.
Nakama, T., O. Nureki, and S. Yokoyama. 2001. Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase. J. Biol. Chem.276:47387-47393.
Novick, R. 1967. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology33:155-166.
O'Neill, A. J., J. H. Cove, and I. Chopra. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J. Antimicrob. Chemother.47:647-650.
Pope, A. J., K. J. Moore, M. McVey, L. Mensah, N. Benson, N. Osbourne, N. Broom, M. J. B. Brown, and P. O'Hanlon. 1998. Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. II. Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics. J. Biol. Chem.273:31691-31701.
Schmitz, F. J., E. Lindenlauf, B. Hofmann, A. C. Fluit, J. Verhoef, H. P. Heinz, and M. E. Jones. 1998. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother.42:489-495.
Silvian, L. F., J. M. Wang, and T. A. Steitz. 1999. Insights into editing from an Ile-tRNA synthetase structure with tRNAIle and mupirocin. Science285:1074-1077.
Sokal, R. R., and J. F. Rohlf. 1973. Introduction to biostatistics. W. H. Freeman, San Francisco, Calif.
Thomas, D. G., J. M. Wilson, M. J. Day, and A. D. Russell. 1999. Mupirocin resistance in staphylococci: development and transfer of isoleucyl tRNA synthetase-mediated resistance in vitro. J. Appl. Microbiol.86:715-722.
Watanabe, H., H. Masaki, N. Asoh, K. Watanabe, K. Oishi, A. Furumoto, S. Kobayashi, A. Sato, and T. Nagatake. 2001. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J. Hosp. Infect.47:294-300.
Watanabe, H., H. Masaki, N. Asoh, K. Watanabe, K. Oishi, S. Kobayashi, A. Sato, R. Sugita, and T. Nagatake. 2001. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol.39:3775-3777.
Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. 1991. A guide to sensitivity testing. J. Antimicrob. Chemother.27(Suppl. D):1-50.
Yanagisawa, T., J. T. Lee, H. C. Wu, and M. Kawakami. 1994. Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli: a proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J. Biol. Chem.269:24304-24309.
Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis.185:561-565.

Information & Contributors


Published In

cover image Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Volume 48Number 11November 2004
Pages: 4366 - 4376
PubMed: 15504866


Received: 6 February 2004
Revision received: 2 May 2004
Accepted: 17 July 2004
Published online: 1 November 2004


Request permissions for this article.



Julian Gregston Hurdle
Antimicrobial Research Centre and School of Biochemistry and Microbiology
Alexander John O'Neill
Antimicrobial Research Centre and School of Biochemistry and Microbiology
Eileen Ingham
Antimicrobial Research Centre and School of Biochemistry and Microbiology
Colin Fishwick
Antimicrobial Research Centre and Department of Chemistry, University of Leeds, Leeds, United Kingdom
Antimicrobial Research Centre and School of Biochemistry and Microbiology

Metrics & Citations


Note: There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.

Citation counts come from the Crossref Cited by service.


If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

View Options

Figures and Media






Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy